Condition: Progressive Myopia · Sponsor: Erasmus Medical Center
The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse. Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year observational period.
This description comes directly from the study's public registry record.
Jan Roelof Polling, Dr. · +31628449254 · j.polling@erasmusmc.nl
Trialbureau Oogheelkunde · +31107039740 · research.oogheelkunde@erasmusmc.nl
Always discuss trial participation with your own doctor first.
| Flevoziekenhuis | Almere Stad, Netherlands | Recruiting |
| OLVG, locatie Oost | Amsterdam, Netherlands | Recruiting |
| Ophthalmologistenpraktijk Delfland | Delft, Netherlands | Recruiting |
| Reinier de Graaf Gasthuis | Delft, Netherlands | Recruiting |
| Deventer Ziekenhuis | Deventer, Netherlands | Recruiting |
| Albert Schweitzer ziekenhuis | Dordrecht, Netherlands | Recruiting |
| Bergman Clinics - Ede | Ede, Netherlands | Recruiting |
| Admiraal de Ruyter Ziekenhuis | Goes, Netherlands | Recruiting |
| Frisius MC | Heerenveen, Netherlands | Recruiting |
| Oogcentrum Noordholland | Heerhugowaard, Netherlands | Recruiting |
| Leiden University Medical Center | Leiden, Netherlands | Recruiting |
| Bergman Clinics - Lelystad | Lelystad, Netherlands | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05667454